1. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. (18th March 2020) Authors: Suzuki, Hiroyoshi; Shin, Toshitaka; Fukasawa, Satoshi; Hashine, Katsuyoshi; Kitani, Sumiko; Ohtake, Noriyuki; Shibayama, Kazuhiro; Tran, Namphuong; Mundle, Suneel; Fizazi, Karim; Matsubara, Nobuaki Journal: Japanese journal of clinical oncology Issue: Volume 50:Number 7(2020) Page Start: 810 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Impact on abiraterone pharmacokinetics and safety: Open‐label drug–drug interaction studies with ketoconazole and rifampicin. Issue 1 (27th June 2014) Authors: Bernard, Apexa; Vaccaro, Nicole; Acharya, Milin; Jiao, James; Monbaliu, Johan; De Vries, Ronald; Stieltjes, Hans; Yu, Margaret; Tran, Namphuong; Chien, Caly Journal: Clinical pharmacology in drug development Issue: Volume 4:Issue 1(2015:Jan./Feb.) Page Start: 63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗